Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Neuroptix, a developer of non-invasive and predictive laser eye scanning test for the early detection and diagnosis of Alzheimer's disease, has raised a total of $18.5 million in its series B funding round, as the company advances its diagnostic test toward clinical trials.
Subscribe to our email newsletter
The investment, led by Inventages, will advance continued development of the Neuroptix Sapphire diagnostic platform and related technologies. The Neuroptix Sapphire system consists of a non-contact optical device combined with an eye drop which specifically identifies Alzheimer’s-related proteins found in the lens of the eye. Rockport Venture Partners acted as the financial advisor on the transaction.
In preclinical testing to date, the system has shown highly promising results, with research showing strong indications that the a-beta proteins associated with the formation of Alzheimer’s-related plaques in the brain can be detected in the eye prior to their aggregation in the brain.
Paul Hartung, president and CEO of Neuroptix, said: “We are very pleased with the results of our successful B round, in support of our efforts to create and commercialize an effective, non-invasive, and early test for Alzheimer’s. Our goal is to help patients, physicians and pharmaceutical companies combat the disease in its earliest stages, where intervention will do the most good.”